The scientific discovery behind Adoram has been published in the Journal of Medicinal Chemistry (ACS Publications). In the original article “Discovery of the First Efficacious Adenosine 2A Receptor Negative Allosteric Modulators for High Adenosine Cancer Immunotherapies”, the team behind Adoram describes the effort produced to to go from a library of thousands of compounds to a few lead compounds. The multidisciplinary team worked hand-in-hand to synthesize original compounds, assess their activity in functional and translational assays, and design new ones based on a rational structure-activity-relationship (SAR) model.
This article has been selected as a featured article, highlighting the significant interest and impact that this article is predicted to have on the medicinal chemistry community, especially groups working on the adenosine 2A receptor (A2AR).
Access to the full text: https://pubs.acs.org/doi/10.1021/acs.jmedchem.4c01691